Quantum Biopharma receives toxicity study reports

Executive Summary

• Quantum Biopharma received final reports for a 90‑day oral toxicity study and a toxicokinetic study of its lead MS candidate Lucid‑MS.
• The data will be used to support an IND filing with the U.S. FDA, moving the program toward a Phase 2 clinical trial in multiple sclerosis.
• Executives highlighted the milestone as a significant step toward launching the first‑in‑class treatment for demyelination in MS patients.

Key Details

• Study Reports Received:
• 90‑day oral toxicity study report for Lucid‑21‑302 (Lucid‑MS).
• Toxicokinetic study report for Lucid‑21‑302 (Lucid‑MS).
• Purpose of Studies: Provide key safety and pharmacokinetic data required for an Investigational New Drug (IND) application to the U.S. FDA.
• Regulatory Path Forward: IND submission anticipated shortly after internal review of the final reports, enabling filing for a Phase 2 clinical trial in multiple sclerosis.
• Executive Comments:
• Dr. Andrzej Chruscinski (VP, Scientific & Clinical Affairs) called receipt of the reports an “important milestone.”
• Anthony Durkacz (Executive Co‑Chairman) emphasized that the data bring Quantum “significantly closer to initiating our phase 2 trial.”
• Drug Candidate: Lucid‑MS (Lucid‑21‑302), a patented new chemical entity designed to prevent and reverse myelin degradation, shown efficacy in preclinical models.

Notable Quotes

“We are pleased that we now have the final reports for these toxicity studies as this represents an important milestone,” – Dr. Andrzej Chruscinski, Vice‑President, Scientific & Clinical Affairs.

“We are very excited about the potential of Lucid‑MS as a first‑in‑class treatment for MS targeting demyelination… With these final reports, we move significantly closer to initiating our phase 2 trial,” – Anthony Durkacz, Executive Co‑Chairman.